hla-a*0201restricted urlc10 peptides with adjuvant
Vaccineexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2011 (NCT01949701)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hla-a*0201restricted urlc10 peptides with adjuvant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01949701 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2011 | Shiga University, University of Tokyo |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shiga University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| University of Tokyo | Academic/Hospital | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1